A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis
|ClinicalTrials.gov Identifier: NCT01119001|
Recruitment Status : Completed
First Posted : May 7, 2010
Results First Posted : June 12, 2015
Last Update Posted : June 12, 2015
|Condition or disease||Intervention/treatment||Phase|
|Amyotrophic Lateral Sclerosis||Device: P300 Brain Computer Interface Keyboard||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||A P300 Brain Computer Interface Keyboard to Control Assistive Technology for People With Amyotrophic Lateral Sclerosis|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
U.S. FDA Resources
|Experimental: P300 Brain Computer Interface for people with ALS||
Device: P300 Brain Computer Interface Keyboard
Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
Other Name: Electrode cap made by Electro-cap International.
- Accuracy of Typing With a BCI Keyboard by ALS Patients. [ Time Frame: 3 times over 2-4 weeks ]
Accuracy for the sentence typed in each environment was calculated as the percentage of characters for which the result character matched the target character. The target characters were determined based on the next character needed to complete the sentence to be copied. In the case of errors, the next character was therefore a backspace to correct the error. The target characters were modified by subject comments to account for errors in selecting the next character.
Once sentence was typed in each environment in each session on a separate day. From the three repeated sessions, there were therefore 9 total sentences per subject with 3 measures for each environment. These were treated as repeated measures for the analysis.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01119001
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Jane Huggins, PhD||University of Michigan|